二甲双胍联用孕激素对非典型增生/子宫内膜上皮内瘤变或子宫内膜癌保留生育治疗的反应影响小且活产率低
结果显示两组完全缓解率与缓解时间无差异,仅17%获得活产且多数需辅助生殖技术。
要点
- 孕激素联合二甲双胍与单用孕激素在完全缓解率及时向上无差异。
- 子宫内膜样癌组织学是与孕激素反应降低相关的唯一因素。
- 仅17%获得活产,其中81%需辅助生殖技术。
核心结论
- 本研究不支持在非典型增生/子宫内膜上皮内瘤变或子宫内膜癌的保留生育治疗中使用孕激素联合二甲双胍。
- 研究期间不足20%的女性获得活产妊娠,且多数需要辅助生殖技术。
研究设计与样本
- 59%(n=54)为非典型增生/子宫内膜上皮内瘤变,41%(n=38)为子宫内膜癌;中位年龄35岁,中位BMI 37.7 kg/m2,中位随访28.4个月。
主要发现
- 总体79%(n=73)对治疗有反应,完全缓解率为69%(n=63)。
- 孕激素联合二甲双胍组与单用孕激素组的完全缓解率(p=0.90)及至完全缓解时间(p=0.31)无差异。
- 总体22%出现疾病复发。
- 多因素分析中,子宫内膜样癌组织学是唯一与孕激素反应降低相关的协变量(HR 0.48;p=0.007)。
- 仅17%的队列获得活产妊娠,其中81%需要辅助生殖技术,且多数发生在单用孕激素组。
临床怎么用
- 对于非典型增生/子宫内膜上皮内瘤变或早期子宫内膜癌要求保留生育的患者,不应常规加用二甲双胍以期提高孕激素反应。
- 应告知患者保留生育治疗后活产率较低且多数需辅助生殖技术。
局限性
- 本研究为回顾性队列研究,可能存在选择偏倚。
- 研究期间仅17%获得活产,活产分析受辅助生殖技术使用及随访时间影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objectives were 1) to compare the efficacy of progestin therapy combined with metformin (Prog-Met) to Prog alone as primary fertility sparing treatment in women with atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) or early-stage endometrioid carcinoma (EC), and 2) to analyze the proportion of women achieving live birth following treatment. METHODS: A retrospective cohort study of all reproductive-aged women with AH/IN or EC treated with Prog ± Met from 1999-2018 was conducted. Complete response (CR) was assessed and Kaplan-Meier analysis used to calculate time to CR. Comparison of potential response predictors was performed with multivariable Cox regression models. RESULTS: Ninety-two women met criteria; 59% (n = 54) were treated for AH/EIN and 41% (n = 38) for EC. Their median age, body mass index, and follow up time was 35 years, 37.7 kg/m2, and 28.4 months, respectively. Fifty-eight women (63%) received Prog and 34 (37%) received Prog-Met. Overall, 79% (n = 73) of subjects responded to treatment with a CR of 69% (n = 63). There was no difference in CR (p = 0.90) or time to CR (p = 0.31) between the treatment cohorts. Overall, 22% experienced a disease recurrence. On multivariable analysis, EC histology was the only covariate associated with a decreased Prog response (HR 0.48; p = 0.007). Only 17% of the cohort achieved a live-birth pregnancy, the majority of which required assisted reproductive technologies (81%) and occurred in the Prog treatment group. CONCLUSIONS: Our study does not support the use of Prog-Met therapy for treatment of AH/EIN or EC. Additionally, fewer than 20% of women achieved a live-birth pregnancy during the study period, with most requiring ART.
引用
- Acosta-Torres S, Murdock T, Matsuno R, et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates. Gynecol Oncol. 2020. PMID: 32085863. doi:10.1016/j.ygyno.2020.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。